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Cervical carcinoma-associated human papillomavirus type 16 (HPV16) encodes E6 and E7 oncoproteins which inactivate
p53 and Rb, respectively, but these interactions are not sufficient to account for the oncogenic potential of the virus. Several
viral promoters were shown to be regulated by E6 and E7. To identify genes as cellular targets of the HPV16 early proteins,
we transfected a new HPV-negative and p53-mutated cervical carcinoma-derived cell line with either the HPV16 full-length
genome or the HPV16 E6 gene. HPV16 clones but not 16E6 clones showed a decreased doubling time that was not related
to the viral DNA and mRNA patterns. In exponentially growing cells as well as in cells synchronized by serum starvation,
expression of the E6 gene was associated with upregulation of the c-fos and c-jun proto-oncogenes and with downregulation
of the c-Ha-ras gene. Furthermore, a viral gene other than E6 may be involved in downregulation of p53 because a reduced
mRNA level at the G1/S transition was observed only in HPV16-cells. The present study on natural host cells indicates
p53-independent transcriptional modulations of cell cycle regulatory genes related to HPV16 E6 and E7 expression. © 1998
Academic Press
INTRODUCTION
Carcinoma of the uterine cervix is a leading cause of
female cancer death. Epidemiological studies have im-
plicated a sexually transmitted agent in the etiology of
this cancer, and molecular analyses have detected on-
cogenic human papillomavirus sequences (mostly HPV
types 16 and 18) in about 85% of invasive cervical can-
cers (Riou et al., 1990). High-risk HPV types are thought
to play a role in the early steps of carcinogenesis by
preventing cell death of infected keratinocytes and ren-
dering them more susceptible to the accumulation of
genetic alterations. Integration of HPV DNA rearranged
sequences into the cellular genome may lead to tumor
progression, with subsequent deregulation of the viral E6
and E7 oncogenes (Baker et al., 1987; Sherman et al.,
1992). In cultured human cells, transfection of genomic
HPV16 DNA or the HPV16 E7 gene results in immortal-
ization but transformation could be achieved by cotrans-
fecting an activated cellular oncogene (Pirisi et al., 1987;
Matlashewski et al., 1988; Mu¨nger et al., 1989). The viral
E6 oncogene was thought to act as a cooperating gene
in the transformation until its intrinsically immortalizing
potential was demonstrated in some cell types (Band et
al., 1991; Storey and Banks, 1993).
The high-risk HPV E6 and E7 genes code for multi-
functional proteins (Vousden, 1993). Their major prop-
erties result in the inactivation of the two tumor sup-
pressor gene products p53 and Rb, respectively
(Dyson et al., 1989; Scheffner et al., 1990; Werness et
al., 1990). The nuclear phosphoprotein p53 mediates
the cellular response to DNA damage (Lane, 1992) by
transactivating genes after binding to specific DNA
sequences, i.e., waf-1, PCNA, and mdm2, but it can
also repress the transcription of some genes including
c-myc, c-fos, and c-jun (Ginsberg et al., 1991; Kley et
al., 1992) by negatively interfering with the basal tran-
scription machinery. In oncogenic HPV-infected cells,
p53 is not available for the transduction of G1 arrest or
apoptosis induced by genotoxic signals (Kessis et al.,
1993; Crook et al., 1994), genetic alterations are repli-
cated, and tumor cells may emerge. The E7 protein
inhibits p53 transcriptional activity (Massimi and
Banks, 1997) and disrupts the complex Rb/E2F, then
precipiting the cells into S phase whatever the genetic
integrity (Demers et al., 1994). However, there is in-
creasing evidence that E6 and p53 as well as E7 and
Rb may act in separate ways. Loss of wild-type p53
function by mutation or antisense strategy does not
cooperate with the HPV16 E7 gene in transformation,
as E6 does (Sedman et al., 1992; Ishiwatari et al.,
1994). The mitotic activity and activation of the telo-
merase by E6 were recently shown to be unrelated to
p53 binding (Klingelhutz et al., 1996; Spitkovsky et al.,
1996). HPV-positive cells exhibit various steady-state
p53 protein levels that are not correlated with E6
expression (Hubbert et al., 1992; Lechner et al., 1992;
Chen et al., 1993a; Holt et al., 1996). Anyway, unde-
tectable p53 levels are sufficient to exert significant
1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 33.1.42.11.52.80.
VIROLOGY 244, 97–107 (1998)
ARTICLE NO. VY989086
0042-6822/98 $25.00
Copyright © 1998 by Academic Press
All rights of reproduction in any form reserved.
97
DNA binding and transactivating activities (Hoppe-
Seyler and Butz, 1993), suggesting that further E6-
and/or E7-associated events may contribute to the
malignancy of HPV-infected cells. In this regard, the E6
protein can transactivate or repress reporter genes
expressed under the control of various viral promoters
(Sedman et al., 1991; Desaintes et al., 1992; Etscheid
et al., 1994; Shirasawa et al., 1994; Akutsu et al., 1996).
Transcriptional activities were shown to be p53-de-
pendent or not and may require the presence of spe-
cific cellular transcription cofactors (Keen et al., 1994;
Chen et al., 1995). Only a few cellular candidate genes
have been reported so far (Morosov et al., 1994; Day et
al., 1997; Kinoshita et al., 1997). The E7 protein also
transactivates and represses some viral promoters by
E2F release or binding to the transcription initiation
complex (Phelps et al., 1988, 1991; Ibaraki et al., 1993;
Mazzarelli et al., 1995; Zwerschke et al., 1996). The
c-myc and c-fos proto-oncogenes were shown to be
transcriptionally repressed by E7 (Robbins et al., 1990;
Morosov et al., 1994). Furthermore, E7 binding to fos
and jun transcription factors (Antinore et al., 1996) may
lead to deregulation of AP1-responsive genes then
participating in the mitogen activity and immortalizing
potential of E7 (Mu¨nger et al., 1989; Sato et al., 1989;
Banks et al., 1990; Morosov et al., 1997).
Therefore, we have transfected HPV16 DNA se-
quences in a new HPV-negative cell line named IGR/
Cut40 which was established from a human invasive
cervical squamous cell carcinoma (Fogel et al., 1995).
These cells carry a mutated p53 gene (CGCArg 3
CACHis at codon 175) encoding an oncogenic protein
(Hinds et al., 1990) lacking specific transcriptional
activities (Chen et al., 1993b; Ory et al., 1994) but
retaining nuclear tetrameric conformation and mdm2
binding (Hinds et al., 1990; Thomas et al., 1995). This
mutant was shown to be resistant to the HPV E6-
induced degradation (Thomas et al., 1995). We have
analyzed the cellular characteristics of HPV16 and
16E6 clones and searched for an association with viral
DNA sequence retention or particular mRNA species.
16E6 cells facilitate analyses of the transforming func-
tion of E6 in the absence of potential interactions with
other viral gene products such as E7. Clonal popula-
tions offer a useful approach to overcoming the inher-
ent complexity of heterogeneous cell populations. We
have studied the expression of some genes involved
in cell proliferation both in exponential growing and in
synchronized cell populations. The eventual mRNA
level differences should be attributable to the HPV16
sequences since all cells carry the cellular genetic
background of the IGR/Cut40 cell line. Furthermore,
the absence of functional p53 in the parental cell line
may point out some activities of viral proteins irrespec-
tive of the complexation or degradation of p53. Finally,
natural host cells express human epithelial-specific
factors that might be necessary for the biological ac-
tivities of HPV16 proteins.
RESULTS
Cellular characteristics
Cotransfection of IGR/Cut40 (parental cells) with
pHPV16 and pSV2neo (HPV16 cells) or pSV2E6-465 and
pSV2neo (16E6 cells) and then subsequent selection in
medium containing G418 antibiotic resulted in the gen-
eration of 5–10 colonies per 5 3 105 treated cells. Trans-
fections were also carried out with pSV2neo alone (con-
trol cells). G418-resistant colonies were pooled up to
passage 3, after which they were either passaged as
polyclonal cultures or separated into different cell popu-
lations by limiting dilution. Six of 8 HPV16 clones (num-
bered 16-1 to 16-6) contained HPV16 DNA and 4 of 12
16E6 clones (numbered E6-1 to E6-4) exhibit the viral E6
gene, as determined by PCR using viral-specific primers
(data not shown). All these clones carried the p53 muta-
tion identified in the parental IGR/Cut40 cell line, as
shown by the migration shift of the p53 exon 5 in single-
stranded conformation polymorphism analysis (data not
shown).
The IGR/Cut40 cell line grew in a monolayer sheet of
small, polygonal, cohesive cells that were occasion-
ally focally piled up. These characteristics were ob-
served for 16E6 clones as well as for HPV16 clones
(data not shown). To determine whether HPV16 se-
quences could act as mitogen activators in the IGR/
Cut40 cells, we examined the growth curves of the
different HPV16 sequence-transfected cell populations
by comparison with parental and control cells using
the MTT assay (Table 1). All HPV16 polyclonal and
monoclonal cells had a 15 to 25% decreased doubling
time including the 16-1 clone if plated at higher den-
sity. By contrast, 16E6 clones showed no significant
difference with parental cells even when they were
cultured at higher density, except for the E6-3 clone
that exhibited a decreased doubling time.
TABLE 1
Doubling Times (dt) of HPV16 and 16E6 Polyclonal Cells at Passage
4 and Monoclonal Cells at Passage 7 Compared to Parental and
Control IGR/Cut40 Cells at Passage 4 after Transfection
Polyclonal
cells
dt
(h)
HPV16
clones
dt
(h)
16E6
clones
dt
(h)
IGR/Cut40 27 16-1 30 E6-1 34
Control (neo) 26 16-2 19 E6-2 27
HPV16 22 16-3 24 E6-3 23
16E6 23 16-4 23 E6-4 28
16-5 23
16-6 20
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HPV16 DNA sequence organization
To determine whether viral DNA structure could
influence cell growth rates, we analyzed HPV16 and
16E6 clones by Southern blot at their 5th passage after
transfection, using HPV16 genomic and subgenomic
probes (Fig. 1). In the 16-4 clone, pHPV16 was present
in its intact monomeric form, as determined by diges-
tion with the no-cut HindIII enzyme (circular form, 12.3
kb) and the cloning site-cutting BamHI enzyme (linear
full-length viral HPV16 DNA, 7.9 kb). The expected A–F
bands are produced by PstI cleavage, although they
are barely detectable. In the other five HPV16 clones,
multiple rearranged bands were observed along with
some expected bands, indicating the integration of
viral sequences at many sites into the chromosomes.
Integration of E6/E7 genes (PstI B fragment) was found
in all clones except 16-2 and that of the E2 gene (PstI
A fragment) in three clones, as determined by hybrid-
ization with HPV16 E6 and E2 probes, respectively
(data not shown). DNA analysis on 16E6 clones
showed the expected restriction fragments corre-
sponding to expression vector in the E6-4 clone, i.e.,
5.1, 1.7, and 2.55 kb after digestion with HindIII, BamHI,
and PstI, respectively (Fig. 1). The vector was therefore
retained under its episomal monomeric form. The ex-
tra bands observed in the E6-4 lanes were nonviral
and were revealed by hybridization using the pSV2neo
plasmid (data not shown). The unexpected specific
hybridization bands in other clones argued for the
integration of E6 sequences within chromosomes.
DNA patterns were observed in the transfectants at
passages 5 through 35. The 16-4 and E6-4 clones
retained intact the expression vector without any inte-
gration or loss of plasmid DNA, while the eight clones
that had early integrated the viral DNA into their ge-
nome did not show further rearrangements.
HPV16 expression
We analyzed the transcriptional activity of viral DNA
sequences by RT–PCR using 16E6-specific primers and
Southern blot (data not shown). All clones exhibited the
expected 93-bp amplified product, while no hybridization
signal was detected for parental and control cells. The
transcriptional activity of HPV16 DNA sequences in
transfected IGR/Cut40 cell populations was further in-
vestigated by Northern blot (Fig. 2). The CaSki cell line
FIG. 1. Southern blot of HPV16 clones (16-1 to 16-6) probed with the HPV16 genome (top) and 16E6 clones (E6-1 to E6-4) probed with the HPV16
E6 fragment (bottom). Undigested DNA (U) and DNA digested by HindIII (H), BamHI (B), and PstI (P) were electrophoresed in a 1% agarose gel,
transferred onto a filter, and hybridized. A lClaI size marker is indicated on the left and some expected restriction fragments of HPV16 and E6 are
shown on the right.
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displayed the expected major HPV16 transcripts of 4.5,
1.5, and 0.7 kb. No signal was observed in parental or
control cells. Both polyclonal HPV16 and 16E6 cells ex-
hibited several viral transcripts which progressively de-
creased in abundancy with passaging. Particular HPV16
mRNA patterns were detected in HPV16-clones with nu-
merous messenger species of various abundance. The
pattern provided by 16-4 clone was consistent with an
episomal genome. In all cells, the E6 probe lighted up
almost all HPV16 bands (data not shown). Clones were
ordered differently according to their viral mRNA levels,
i.e., 16-2, 16-1, 16-3, 16-6, 16-4, 16-5 with the E6 probe
instead of 16-1 to 16-6 with the genomic probe. The
expected 1.5-kb E6 mRNA from the E6 expression vector
was detected in all 16E6 clones including the E6-1 clone
upon longer exposure. The origin of higher molecular
weight bands observed in the E6-4 clone was unknown.
Viral mRNA patterns from monoclonal cells were quan-
titatively and qualitatively stable in long-term culture.
Expression of growth-regulating genes in exponential
and synchronous cultured cells
We analyzed the expression of genes involved in cell
proliferation by Northern blot hybridization sequentially
using probes specific for p53, c-fos, c-Ha-ras, c-jun,
c-myc, and mdm2. RNAs were obtained from exponen-
tially growing HPV16 and 16E6 cells with distinct HPV16
DNA sequences and mRNA patterns. Data obtained for
p53, c-fos, and c-Ha-ras genes in 16E6 polyclonal (p) and
monoclonal (1 to 4) cells are presented in Fig. 3 accord-
ing to the content of viral mRNA. pSV2neo-transfected
cells exhibited gene expression similar to that of paren-
tal cells. The p53 mRNA level did not significantly vary,
whereas the mRNA level of c-fos increased and that of
c-Ha-ras decreased with higher E6 transcript levels. In-
creased E6 expression was associated with elevated
c-jun mRNA levels and a reduced c-myc mRNA level,
except for E6-3 exhibiting a dramatic overexpression. No
variation of mdm2 mRNA level was detected (Table 2).
Similar modulation of gene expression was obtained in
HPV16 cells except for the p53 transcript, whose level
moderately decreased with increased viral expression.
To better analyze the effect of HPV16 functions on
gene expression, mRNAs corresponding to the different
genes were studied in synchronized HPV16 and 16E6
polyclonal cells and in clones expressing the highest
levels of viral mRNA (16-6 and E6-4). Two independent
experiments yielding identical results were performed
with synchronized cells. In the first experiment, cells
were collected with longer time intervals as in the sec-
ond experiment (8 cell aliquots harvested every 2 or 4 h
vs 12 cell aliquots harvested every 1.5 or 3 h), as shown
in Fig. 5. As determined by flow cytometry (data not
shown), 70 to 80% of the serum-starved cells were syn-
chronized but cells rapidly grew asynchronously. Total
RNAs extracted from cells 1 to 25 h after serum addition
FIG. 2. Northern blot of HPV16 cells and 16E6 cells. Total RNA (10 mg) was electrophoresed in a 1.2% denaturing agarose gel, stained with ethidium
bromide (lower panel), transferred onto a filter, and hybridized with a full-length HPV16 probe for HPV16 cells and a specific HPV16 E6 probe for 16E6
cells (upper panel). RNA from the CaSki cell line (1 mg) was used as positive control and RNAs from IGR/Cut40 and control pSV2neo-transfected cells
were used as negative controls.
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(time 0) were analyzed by Northern blot (Fig. 4). The E6-4
clone was fully representative of polyclonal cells,
whereas the 16-6 clone was not because of its constitu-
tive HPV16 expression during the cell cycle (data not
shown). Both polyclonal HPV16 cells and polyclonal 16E6
cells showed elevated viral mRNA expression in G1
phase (Fig. 5). Although exhibiting abnormal mRNA lev-
els in exponentially growing IGR/Cut40 cells (data not
shown), c-jun, c-myc, p53, and c-Ha-ras genes showed
their cell cycle-regulated expression, as previously re-
ported (Kelly et al., 1983; Reich and Levine, 1984; Cala-
bretta et al., 1986; Ryseck et al., 1988; Gudas et al., 1994;
Katsumoto et al., 1995). Interestingly, we observed that
the p53 mRNA peak was inhibited at the G1/S transition
in HPV16 cells but not in 16E6 cells. As concerns c-fos
mRNA, 16E6 cells showed elevated mRNA level through-
out the G1 phase, while HPV16 cells as well as control
cells exhibited an unexpected peak in S phase in addi-
FIG. 3. Quantification of p53, c-fos, and c-Ha-ras mRNA levels determined by Northern blot in exponentially growing 16E6 polyclonal and
monoclonal cells. Polyclonal cells were harvested at passages 2, 4, and 10 (p2, p4, p10) and RNAs were analyzed in duplicate. For the four clones
(1, 2, 3, 4), results are the mean of expression levels observed at passages 5, 15, 25, and 35 for each clone. Standard error bars are indicated. Cells
are ordered according to their E6 mRNA levels expressed in arbitrary units (a.u.) calculated from CaSki cells. For cellular gene expression, 1 a.u.
corresponds to the mRNA level detected in parental IGR/Cut40 cells after normalization by 28S RNA (see Materials and Methods).
TABLE 2
mRNA Levels of Some Genes Involved in Cell Proliferation in Asynchronous HPV16 and 16E6 IGR/Cut40 Cells Compared
with Control pSV2neo-Transfected IGR/Cut40 Cells
Genes
mRNA levels in asynchronous cells mRNA levels in synchronized cells
HPV16 cells 16E6 cells Probable mechanism Associated with
p53 Decreased No change Abolition of G1/S peak Gene other than E6
c-fos Increased Increased Prolonged G1 peak E6
c-jun Increased Increased Prolonged G1 peak E6
c-Ha-ras Decreased Decreased Inhibition of S peak E6
c-myc Decreased Decreased G1 shortening —
mdm2 No change No change — —
Note. Underlying mechanisms as suggested by synchronization experiments on HPV16 and 16E6 IGR/Cut40 cells.
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tion to the immediate early one (Greenberg and Ziff,
1984; Mu¨ller et al., 1984). Both HPV16 and 16E6 cells
showed a reduced c-Ha-ras mRNA peak in S phase and
a prolonged c-jun mRNA peak in G1 phase (Table 2). The
biphasic expression of the c-myc gene in early G1 and S
phases was observed in all cells. No mdm2 mRNA level
variation was detected in any cell population. In con-
clusion, cell cycle-regulated expression of the c-fos,
c-Ha-ras, and c-jun genes may be disrupted in HPV-
infected cells by E6 expression and those of p53 by
another viral gene.
DISCUSSION
Oncogenic HPV types are associated with 85% of
invasive cervical cancer and their immortalizing proper-
ties have been demonstrated in numerous in vitro exper-
iments. In addition to the ability of E6 and E7 oncopro-
teins to interact with p53 and Rb, respectively (Dyson et
al., 1989; Scheffner et al., 1990; Werness et al., 1990),
several lines of evidence suggest p53- and Rb-indepen-
dent viral functions (Vousden, 1993). E6 and E7 oncop-
roteins are able to transactivate or repress several viral
promoters. Transcriptional modulation of key genes in-
volved in the cell proliferation control may constitute a
p53-independent transforming activity for HPV16 E6 and
E7. In attempt to evaluate this hypothesis, we have ana-
lyzed mRNA levels of some proto-oncogenes and anti-
oncogenes in HPV16 sequence-transfected cells of hu-
man epithelial origin that do not contain functional p53.
In the first part of the present study, we characterized
six HPV16 clones and four 16E6 clones derived from the
IGR/Cut40 cell line (Fogel et al., 1995). The increased
proliferation rate observed in HPV16 clones but not in
16E6 clones (Table 1) shows that HPV16 gene expres-
sion alters the cell cycle even in tumor cells. This effect
is likely mediated by E7, whose mitogenic activity was
previously reported in nontumoral cells (Sato et al., 1989;
Banks et al., 1990). The decreased doubling time of the
pooled 16E6 cell culture may be explained by its high
content of clones for which random integration of the
vector has been linked to activation of other genes in-
volved in cell proliferation than those studied in Table 2.
The growth rate of HPV16 clones was not closely related
to viral E6/E7 messenger levels (Fig. 2). The episomal or
integrated form of the vector and the amount of HPV16
DNA (Fig. 1) were not associated with growth properties
either.
The degree of amplification of E6/E7 genes greatly
varied among HPV16 clones (,0.1 to 5 copies per cell)
but not in 16E6 clones (Fig. 1), suggesting a crucial role
FIG. 4. Northern blot of synchronized control pSV2neo-transfected, polyclonal 16E6, and polyclonal HPV16 cells harvested at different times (1 to
25 h) after serum addition. Blots were sequentially hybridized with HPV16 (full-length genome for HPV16 cells or an HPV16 E6 fragment for 16E6 cells),
p53, c-fos, and c-Ha-ras probes. Agarose gels were stained by ethidium bromide (EB) showing the 28S and 18S RNA species.
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for another viral gene than E6 in the amplification pro-
cess that was linked to integration into the cellular ge-
nome. In the 16-4 and E6-4 clones, the persistence over
35 passages without any drug selection of the trans-
fected vector under its episomal state was quite surpris-
ing and not usually observed (Choo et al., 1989; Stanley
et al., 1989). These clones are useful tools for studying
HPV16 functions in the absence of any cellular genetic
alterations associated with random viral integration.
HPV16 DNA sequences were found to be transcrip-
tionally active in all the transfected cells but mRNA spe-
cies varied in size and in abundance (Fig. 2). High mRNA
levels were not correlated with viral DNA amount or
deletion of the E2 gene (Fig. 1) encoding a negative
regulator of the early promoter (Tan et al., 1992). Viral
expression may rather depend on the chromosomal lo-
cation of HPV16 sequences and their accessibility to the
transcription machinery. Almost all HPV16 transcripts
encode E6 and E7 (data not shown), some of them may
be generated by HPV16 DNA sequence rearrangements,
while others may be naturally occurring spliced forms
encoding functional proteins. Western blot experiments
on unlabeled cells failed to detect any E6 and E7 pro-
teins, probably present at very low levels (Schneider-
Maunoury et al., 1987; Seedorf et al., 1987). However,
since cellular transcription factors act very efficiently, we
searched for an abnormal expression of cellular genes
known to play a key role in the proliferation that may be
linked to viral expression.
mRNA levels of p53, c-Ha-ras, c-fos, c-jun, c-myc, and
mdm2 were analyzed in IGR/Cut40-derived cells carrying
various viral characteristics. Cellular mRNA levels ob-
served in exponentially growing cells (Fig. 3) could be
explained by our two independent experiments with syn-
chronized cells (Fig. 5 and data not shown). Correlation
between cellular gene expression and viral gene expres-
sion was apparent in polyclonal cells and less evident in
clonal cells (Fig. 3), for which distinct genetic defects
linked to vector integration may mask the viral activities.
HPV16 cells but not 16E6 cells displayed lower p53
mRNA levels than those detected in parental and control
cells in relation to the inhibition of the p53 mRNA peak at
the G1/S transition. The p53 promoter may be transcrip-
tionally modulated by E7, as previously shown for c-myc
and c-fos promoters (Robbins et al., 1990; Morosov et al.,
1994). However, further cotransfection assays using an
HPV16 E7 expression vector are required to show that
the decreased p53 mRNA level in our model is due to an
inhibitory effect of E7 on the promoter. Interestingly, such
a p53 downregulation at the G1/S transition was also
FIG. 5. Quantification of viral, p53, c-fos, and c-Ha-ras mRNA levels shown in Fig. 4 in synchronized polyclonal HPV16 (— } —) and 16E6 (— { —)
cells compared with control pSV2neo-transfected cells (– – h – –). Amounts of RNA loaded in each lane were normalized with 28S RNA bands.
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observed in an HPV16-positive and wild-type p53 cervi-
cal carcinoma-derived cell line (unpublished results).
Moreover, p53 accumulation at the G1/S transition is
necessary for cell cycle control in synchronized nontu-
moral cells cultured without genotoxic stress (Reich and
Levine, 1984; Mercer and Baserga, 1985; Calabretta et
al., 1986; Gudas et al., 1994; Katsumoto et al., 1995). It is
tempting to speculate that E7 acts in concert with E6 to
downregulate the p53 activity in HPV-infected cervical
cells.
A striking finding of this study is that the immediate
early response c-fos and c-jun genes could be upregu-
lated by E6 independently of p53. Disruption by E6 of
their retroregulation that is required for transient ex-
pression may lead to a cascade of gene expression. In
addition, our study shows that the c-Ha-ras gene was
downregulated in HPV16 and 16E6 cells yet AP1-re-
sponsive, indicating multiple pathways involved in that
expression. The early response c-myc gene (Mu¨ller et
al., 1984) was slightly downregulated in both trans-
fected populations that may be related to the G1 phase
shortening (data not shown). In one 16E6 clone, dra-
matic c-myc overexpression without gene rearrange-
ment (Southern blot, not shown) may be consequent to
proximal integration of the vector containing strong
promoters, as previously reported (Couturier et al.,
1991). Our results do not argue for c-myc transactiva-
tion by viral proteins, as observed in nonnatural host
cells (Crook et al., 1989; Kinoshita et al., 1997), but
agree with those of c-fos transactivation (Robbins et
al., 1990; Morosov et al., 1994). In conclusion, dereg-
ulated expression of numerous genes involved in cell
proliferation may be implicated in the mitogenic and
oncogenic potential of HPV16.
In this report, we have characterized subclones of a
new cervical carcinoma-derived cell line which has been
transfected by either the HPV16 full-length genome or the
HPV16 E6 gene. To our knowledge, no stable model
bearing both p53 mutation and HPV16 sequences has
been previously established. Subsequent studies focus-
ing on cellular genes involved in proliferation should give
further insight into the transcriptional regulatory proper-
ties of the HPV16 E6 and E7 oncoproteins that would be
dependent on epithelial factors but unrelated to p53
function.
MATERIALS AND METHODS
Exponential and synchronous cell growth
IGR/Cut40 cells were grown in DMEM 4.5 g/L glucose
(Gibco BRL) supplemented with 10% heat-inactivated fe-
tal calf serum (Gibco), 2 mM L-glutamine, 100 units/ml
penicillin, 10 mg/ml gentamycin, and 5 mg/ml amphoter-
icin in 8% CO2 at 37°C.
Growth curves were determined by MTT assay (Mos-
mann, 1983) on cells seeded at varying concentrations in
96-well plates and harvested at regular intervals follow-
ing the addition of 40 ml of a 2.5 mg/ml solution of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, Sigma) to each well for 4 h at 37°C. Colorimetric
reading was done at 540 nm after addition of 100 ml of
dimethyl sulfoxide. For each cell population, the number
of cells corresponding to the average optical density
from 16 wells was plotted as a function of time. Doubling
time was determined by the inverse of the slope of the
best-fit line calculated by linear regression of the log of
the cell counts. Experiments were performed in triplicate.
For experiments requiring synchronous cells, 7 3 105
IGR/Cut40 cells per 80-cm2 culture flask were grown in
complete medium for 2 days and then deprived of serum
for 72 h. After addition of serum, cells were trypsinized at
regular intervals for DNA content and RNA analyses.
Transfection experiments
IGR/Cut40 cells at the 83rd passage (5 3 105 per
10-mm petri dish) were transfected with PSV2neo or
cotransfected with 36 mg pHPV16 or 15 mg pSV2E6-465
and pSV2neo (molar ratio 3:1) using the calcium phos-
phate precipitation method. pHPV16, kindly provided by
G. Orth (Unite´ des Papillomavirus, INSERM, U190, Institut
Pasteur, Paris, France), contains the full-length HPV16
DNA cloned at the BamHI site of pBR322. PSV2E6-465
contains the HPV16 E6 gene (632-bp DdeI–DdeI HPV16
DNA fragment) with a mutation stop in the 59 part of the
E7 gene that may be driven by its own promoter and the
SV40 early promoter (Desaintes et al., 1992). After 16 h
with the DNA precipitate, cells were incubated in growth
medium for 24 h and then maintained in culture medium
containing 500 mg/ml G418 (Sigma) for 6 weeks. G418-
resistant colonies at passage 3 were seeded at low
density by serial dilution into 96-well plates. Clones
which grew as a single colony in a well were picked out
by trypsinization and subcultured into flasks.
Cytofluorimetric analyses
Cell nuclei were obtained by treatment on ice for 30
min with hypotonic Tris buffer, pH 7.6, containing 0.1%
NP-40, 50 mg/ml propidium iodide, and 1 mg/ml ribonu-
clease A. The resulting suspension was passed through
a 37-mm nylon mesh before analysis with a EPICS C flow
cytometer (Coultronics, Hialeah, FL). Twenty thousand
nuclei were analyzed for DNA content and percentages
of cells in G0/G1, S, and G2/M phases were calculated
from the histograms.
Nucleic acid hybridizations
DNA and total RNA were extracted by the guanidinium
isothiocyanate–CsCl gradient (Sheng et al., 1990). DNA
was dialyzed, treated with 0.2 mg/ml proteinase K, and
deproteinized by phenol–CHCl3. Undigested or restric-
tion endonuclease-cleaved DNA (5 mg per well) was
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fractionated on a 1% agarose gel, denatured, and then
transferred onto a Biodyne B membrane. Hybridizations
with [32P]dCTP random-prime full-length HPV16 DNA or
632-bp DdeI–DdeI HPV16 DNA were performed in 50%
formamide, 53 SSC, 53 Denhardt, 1% SDS, 20 mM
Na2HPO4/NaH2PO4, pH 6.8, and 100 mg/ml salmon
sperm DNA at 42°C for 24 h. Filters were washed in 23
SSC, 1% SDS at 65°C for 1 h followed by 0.13 SSC, 0.1%
SDS at room temperature for 30 min. Blots were exposed
for various periods of time to Amersham Hyper Films
M.P. at 270°C.
The pellet of total RNA was solubilized in 10 mM
Tris–HCl, pH 7.5, 1 mM EDTA, pH 8, 0.1% SDS and
precipitated with absolute ethanol. Total RNA (10 mg per
well) was electrophoresed in a 1.2% denaturing formal-
dehyde agarose gel and transferred to a filter. Blots were
hybridized as described above and washed in 0.53 SSC,
1% SDS at 65°C for 1 h and then 0.13 SSC, 0.1% SDS at
room temperature for 30 min. The autoradiographic films
were scanned to quantitate the abundance of specific
transcripts (Chromoscan III, Joyce Loebl). Values were
corrected for the amount of RNA loaded in each lane as
determined by ethidium bromide staining of the 28S RNA
band photographed under ultraviolet light. In exponen-
tially growing cells, the intensity of the 28S RNA paral-
leled the intensity of the hybridization band of the house-
keeping b-actin gene (data not shown). In contrast, stan-
dardization by b-actin gene expression was unsuitable
for synchronized cells because its expression was
shown to be cell cycle-regulated (Corjay et al., 1989).
Several control samples were included in each gel in
order to standardize the values between the blots after
normalization by 28S RNA. One arbitrary unit (a.u.) cor-
responds to the level of cellular mRNA detected in ex-
ponentially growing IGR/Cut40 cells. For viral mRNA
quantification, 100 a.u. corresponds to the level of viral
mRNA detected in CaSki cells using the same probe.
Detection of HPV16 DNA and RNA by polymerase
chain reaction
Genomic DNA (500 ng) in 100 ml of reaction buffer
containing 1 unit of Taq polymerase (Promega), 125 mM
dNTPs, and 4 pmol of the HPV16 E6-specific primer pair
(nt 496–589 of the HPV16 sequence) was subjected to 30
cycles of amplification, each of 1 min at 94°C, 1 min at
57°C, and 2 min at 72°C. Twenty microliters of the
reaction product was electrophoresed on a 2% agarose
gel and transferred onto a filter. Hybridization was car-
ried out at 68°C with a 32P random-prime-labeled 632-bp
DdeI–DdeI HPV16 fragment in 7% SDS, 1 mM EDTA, 0.25
M NaPO4, pH 7. The blot was washed at high stringency
in 33 SSC, 0.5% SDS for 1 h at room temperature and
then exposed to autoradiographic films.
Total RNA was treated with 1 U/mg DNase I for 15 min
at 25°C and purified with RNazol/CHCl3 (Bioprobe).
cDNA synthesis was obtained with 200 units/0.6 mg RNA
of SuperScript reverse transcriptase (Gibco) according to
the manufacturer’s instructions. Products were subjected
to a PCR followed by Southern blotting as described
above.
ACKNOWLEDGMENTS
We thank F. Breitburd (Unite´ des Papillomavirus, Institut Pasteur,
Paris, France) for fruitful discussions, M. Barrois and J. C. Ahomadegbe
for helpful molecular advice, and J. Da Silva for skillful technical assis-
tance in cell culture experiments. This work was supported by grants
from the Association pour la Recherche contre le Cancer (Villejuif).
REFERENCES
Akutsu, N., Shirasawa, H., Asano, T., Isono, K., and Simizu, B. (1996).
p53-dependent and -independent transactivation by the E6 protein of
human papillomavirus type 16. J. Gen. Virol. 77, 459–463.
Antinore, M. J., Birrer, M. J., Patel, D., Nader, L., and McCance, D. J.
(1996). The human papillomavirus type 16 E7 gene product interacts
with and transactivates the AP1 family of transcription factors. EMBO
J. 15, 1950–1960.
Baker, C. C., Phelps, W. C., Lindgren, V., Braun, M. J., Gonda, M. A., and
Howley, P. M. (1987). Structural and transcriptional analysis of human
papillomavirus type 16 sequences in cervical carcinoma cell lines.
J. Virol. 61, 962–971.
Band, V., De Caprio, J. A., Delmolino, L., Kulesa, V., and Sager, R. (1991).
Loss of p53 protein in human papillomavirus type 16 E6-immortalized
human mammary epithelial cells. J. Virol. 65, 6671–6676.
Banks, L., Edmonds, C., and Vousden, K. H. (1990). Ability of the HPV16
E7 protein to bind RB and induce DNA synthesis is not sufficient for
efficient transforming activity in NIH3T3 cells. Oncogene 5, 1383–
1389.
Calabretta, B., Kaczmarek, L., Selleri, L., Torelli, G., Ming, P. M. L., Ming,
S. C., and Mercer, W. E. (1986). Growth-dependent expression of
human Mr 53,000 tumor antigen messenger RNA in normal and
neoplastic cells. Cancer Res. 46, 5738–5742.
Chen, J. J., Reid, C. E., Band, V., and Androphy, E. J. (1995). Interaction of
papillomavirus E6 oncoproteins with a putative calcium-binding pro-
tein. Science 269, 529–531.
Chen, T. M., Chen, C. A., Hsieh, C. Y., Chang, D. Y., Chen, Y. H., and
Defendi, V. (1993a). The state of p53 in primary human cervical
carcinomas and its effects in human papillomavirus-immortalized
human cervical cells. Oncogene 8, 1511–1518.
Chen, J. Y., Funk, W. D., Wright, W. E., Shay, J. W., and Minna, J. D.
(1993b). Heterogeneity of transcriptional activity of mutant p53 pro-
teins and p53 DNA target sequences. Oncogene 8, 2159–2166.
Choo, K. B., Chong, K. Y., Chou, H. F., Liew, L. N., and Liou, C. C. (1989).
Analysis of the structure and expression of the c-myc oncogene in
cervical tumor and in cervical tumor-derived cell lines. Biochem.
Biophys. Res. Commun. 158, 334–340.
Corjay, M. H., Thompson, M. M., Lynch, K. R., and Owens, G. K. (1989).
Differential effect of platelet-derived growth factor- versus serum-
induced growth on smooth muscle alpha-actin and non-muscle beta-
actin mRNA expression in cultured rat aortic smooth muscle cells.
J. Biol. Chem. 264, 10501–10506.
Couturier, J., Sastre-Garau, X., Schneider-Maunoury, S., Labib, A., and
Orth, G. (1991). Integration of Papillomavirus DNA near myc genes in
genital carcinomas and its consequences for proto-oncogene ex-
pression. J. Virol. 65, 4534–4538.
Crook, T., Almond, N., Murray, A., Stanley, M., and Crawford, L. (1989).
Constitutive expression of c-myc oncogene confers hormone inde-
pendence and enhanced growth-factor responsiveness on cells
transformed by human papillomavirus type 16. Proc. Natl. Acad. Sci.
USA 86, 5713–5717.
105HPV16, P53, AND ONCOGENES IN CERVICAL CELLS
Crook, T., Fisher, C., Masterson, P. J., and Vousden, K. H. (1994).
Modulation of transcriptional regulatory properties of p53 by HPV E6.
Oncogene 9, 1225–1230.
Day, A., Atcha, I. A., and Bagchi, S. (1997). HPV16 E6 oncoprotein
stimulates the transforming growth factor-beta 1 promoter in fibro-
blasts through a specific GC-rich sequence. Virology 228, 190–199.
Demers, G. W., Foster, S. A., Halbert, C. L., and Galloway, D. A. (1994).
Growth arrest by induction of p53 in DNA damaged keratinocytes is
bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA
91, 4382–438.
Desaintes, C., Hallez, S., Van Alphen, P., and Burny, A. (1992). Transcrip-
tional activation of several heterologous promotors by the E6 protein
of HPV type 16. J. Virol. 66, 325–333.
Dyson, N., Howley, P. M., Mu¨nger, K., and Harlow, E. (1989). The human
papilloma virus-16 E7 oncoprotein is able to bind to the retinoblas-
toma gene product. Science 243, 934–940.
Etscheid, B. G., Foster, S. A., and Galloway, D. A. (1994). The E6 protein
of human papillomavirus type 16 functions as a transcriptional re-
pressor in a mechanism independent of the tumor suppressor pro-
tein, p53. Virology 205, 583–585.
Fogel, S., Ahomadegbe, J. C., Le Bihan, M. L., Barrois, M., and Riou, G.
(1995). Characterization of a new p53-mutated and HPV-negative
human squamous cell cervical carcinoma-derived cell line. Int. J.
Oncol. 6, 681–686.
Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. (1991). Wild-type p53
down-modulate the activity of various promoters. Proc. Natl. Acad.
Sci. USA 88, 9979–9983.
Greenberg, M. E., and Ziff, E. B. (1984). Stimulation of 3T3 cells induces
transcription of the c-fos proto-oncogene. Nature 311, 433–438.
Gudas, J. M., Oka, M., Diella, F., Trepel, J., and Cowan, K. H. (1994).
Expression of wild-type p53 during the cell cycle in normal human
mammary epithelial cells. Cell Growth Differ. 5, 295–304.
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R.,
Vogelstein, B., and Levine, A. J. (1990). Mutant p53 DNA clones from
human colon carcinomas cooperate with ras in transforming primary
rat cells: A comparison of the ‘‘hot spot’’ mutant phenotypes. Cell
Growth Differ. 1, 571–580.
Holt, S. E., Gollahon, L. S., Willingham, T., Barbosa, M. S., and Shay, J. W.
(1996). p53 levels in human mammary epithelial cells expressing
wild-type and mutant papillomavirus type 16 (HPV-16) E6 proteins:
Relationship to reactivation of telomerase and immortalisation. Int. J.
Oncol. 8, 263–270.
Hoppe-Seyler, F., and Butz, K. (1993). Repression of endogenous p53
transactivation functions in HeLa cervical carcinoma cells by human
papillomavirus type 16 E6, human mdm-2, and mutant p53. J. Virol. 67,
3111–3117.
Hubbert, N. L., Sedman, S. A., and Schiller, J. T. (1992). HPV type 16 E6
protein increases the degradation rate of p53 in human keratino-
cytes. J. Virol. 66, 6237–6241.
Ibaraki, T., Satake, M., Kurai, N., Ichijo, M., and Ito, Y. (1993). Transacting
activities of the E7 genes of several types of human papillomavirus.
Virus Genes 7, 187–196.
Ishiwatari, H., Hayasaka, N., Inoue, H., Yutsudo, M., and Hakura, A.
(1994). Degradation of p53 only is not sufficient for the growth
stimulatory effect of human papillomavirus 16 E6 oncoprotein in
human embryonic fibroblasts. J. Med. Virol. 44, 243–249.
Katsumoto, T., Higaki, K., Ohno, K., and Onodera, K. (1995). Cell-cycle
dependent biosynthesis and localization of p53 protein in untrans-
formed human cells. Biol. Cell. 84, 167–173.
Keen, N., Elston, R., and Crawford, L. (1994). Interaction of the E6
protein of human papillomavirus with cellular proteins. Oncogene 9,
1493–1499.
Kelly, K., Cochran, B. H., Stiles, C. D., and Leder, P. (1983). Cell-specific
regulation of the c-myc gene by lymphocyte mitogens and platelet-
derived growth factor. Cell 35, 603–610.
Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S.,
Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. (1993). HPV16 E6
expression disrupts the p53-mediated cellular response to DNA
damage. Proc. Natl. Acad. Sci. USA 90, 3988–3992.
Kinoshita, T., Shirasawa, H., Shino, Y., Moriya, H., Desbarats, L., Eilers,
M., and Simizu, B. (1997). Transactivation of prothymosin alpha and
c-myc promoters by human papillomavirus type 16 E6 protein. Virol-
ogy 232, 53–61.
Kley, N., Chung, R. Y., Fay, S., Loeffler, J. P., and Seizinger, B. R. (1992).
Repression of basal c-fos promoter by wild-type p53. Nucleic Acids
Res. 20, 4083–4087.
Klingelhutz, A. J., Foster, S. A., and McDougall, J. K. (1996). Telomerase
activation by the E6 gene product of human papillomavirus type 16.
Nature 380, 79–82.
Lane, D. P. (1992). p53, guardian of the genome. Nature 358, 15–16.
Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H., and
Laimins, L. A. (1992). Human papillomavirus E6 proteins bind p53 in
vivo and abrogate p53-mediated repression of transcription. EMBO J.
11, 3045–3052.
Massimi, P., and Banks, L. (1997). Repression of p53 transcriptional
activity by the HPV E7 proteins. Virology 227, 255–259.
Matlashewski, G., Osborn, K., Banks, L., Stanley, M., and Crawford, L.
(1988). Transformation of primary human fibroblast cells with human
papillomavirus type 16 DNA and EJ-ras. Int. J. Cancer 42, 232–238.
Mazzarelli, J. M., Atkins, G. B., Geisberg, J. V., and Ricciardi, R. P. (1995).
The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40 T Ag bind a
common region of the TBP-associated factor-110. Oncogene 11,
1859–1864.
Mercer, W. E., and Baserga, R. (1985). Expression of the p53 protein
during the cell cycle of human peripheral blood lymphocytes. Exp.
Cell. Res. 160, 31–46.
Morosov, A., Phelps, W. C., and Raychaudhuri, P. (1994). Activation of
the c-fos gene by the HPV16 oncoproteins depends upon the cAMP-
responsive element at 260. J. Biol. Chem. 269, 18434–18440.
Morosov, A., Shiyanov, P., Barr, E., Leiden, J. M., and Raychaudhuri, P.
(1997). Accumulation of human papillomavirus type 16 E7 protein
bypasses G1 arrest induced by serum deprivation and by the cell
cycle inhibitor p21. J. Virol. 71, 3451–3457.
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and
survival: Application to proliferation and cytotoxicity assays. J. Immu-
nol. Methods 65, 55.
Mu¨ller, R., Bravo, R., and Burckhardt, J. (1984). Induction of c-fos gene
and protein by growth factors precedes activation of c-myc. Nature
312, 716–720.
Mu¨nger, K., Phelps, W. C., Bubb, V., Howley, P. M., and Schlegel, R.
(1989). The E6 and E7 genes of the human papillomavirus type 16
together are necessary and sufficient for transformation of primary
human keratinocytes. J. Virol. 63, 4417–4421.
Ory, K., Legros, Y., Auguin, C., and Soussi, T. (1994). Analysis of the most
representative tumour-derived p53 mutants reveals that changes in
protein conformation are not correlated with the loss of transactiva-
tion or inhibition of cell proliferation. EMBO J. 13, 3496–3504.
Phelps, W. C., Yee, C. L., Mu¨nger, K., and Howley, P. M. (1988). The
human papillomavirus type 16 E7 gene encodes transactivation and
transformation functions similar to those of adenovirus E1A. Cell 53,
539–547.
Phelps, W. C., Bagchi, S., Barnes, J. A., Raychaudhuri, P., Kraus, V.,
Mu¨nger, K., Howley, P. M., and Nevins, J. R. (1991). Analysis of trans
activation by human papillomavirus type 16 E7 and adenovirus 12S
E1A suggests a common mechanism. J. Virol. 65, 6922–6930.
Pirisi, L., Yasumoto, S., Feller, M., Doniger, J., and DiPaolo, J. A. (1987).
Transformation of human fibroblasts and keratinocytes with human
papillomavirus type 16 DNA. J. Virol. 61, 1061–1066.
Reich, N. C., and Levine, A. J. (1984). Growth regulation of a cellular
tumour antigen, p53, in nontransformed cells. Nature 308, 199–201.
Riou, G., Favre, M., Jeannel, D., Bourhis, J., Le Doussal, V., and Orth, G.
(1990). Association between poor prognosis in early-stage invasive
cervical carcinomas and non-detection of HPV DNA. Lancet 335,
1171–1174.
106 FOGEL AND RIOU
Robbins, P. D., Horowitz, J. M., and Mulligan, R. C. (1990). Negative
regulation of human c-fos expression by the retinoblastoma gene
product. Nature 346, 668–671.
Ryseck, R. P., Hirai, S. I., Yaniv, M., and Bravo, R. (1988). Transcriptional
activation of c-jun during the G0/G1 transition in mouse fibroblasts.
Nature 334, 535–537.
Sato, H., Furuno, A., and Yoshiike, K. (1989). Expression of human
papillomavirus type 16 E7 gene induces DNA synthesis of rat 3Y1
cells. Virology 168, 195–199.
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and
Howley, P. M. (1990). The E6 oncoprotein encoded by human papil-
lomavirus 16 and 18 promotes the degradation of p53. Cell 63,
1129–1136.
Schneider-Maunoury, S., Croissant, O., and Orth, G. (1987). Integration
of human papillomavirus type 16 DNA sequences: A possible early
event in the progression of genital tumors. J. Virol. 61, 3295–3298.
Sedman, S. A., Barbosa, M. S., Vass, W. C., Hubbert, N. L., Haas, J. A.,
Lowy, D. R., and Schiller, J. T. (1991). The full-length E6 protein of
human papillomavirus type 16 has transforming and trans-activating
activities and cooperates with E7 to immortalize keratinocytes in
culture. J. Virol. 65, 4860–4866.
Sedman, S. A., Hubbert, N. L., Vass, W. C., Lowy, D. R., and Schiller, J. T.
(1992). Mutant p53 can substitute for human papillomavirus type 16
E6 in immortalization of human keratinocytes but does not have
E6-associated trans-activation or transforming activity. J. Virol. 66,
4201–4208.
Seedorf, K., Oltersdorf, T., Krammer, G., and Rowekamp, W. (1987).
Identification of early proteins of the human papilloma viruses type
16 and type 18 in cervical carcinoma cells. EMBO J. 6, 139–144.
Sheng, Z. M., Barrois, M., Klijanienko, J., Micheau, C., Richard, J. M., and
Riou, G. (1990). Analysis of the c-Ha-ras-1 gene for deletion, ampli-
fication and expression in lymph node metastases of head and neck
carcinomas. Br. J. Cancer 62, 398–404.
Sherman, L., Alloul, N., Golan, I., Du¨rst, M., and Baram, A. (1992).
Expression and splicing patterns of human papillomavirus type-
16 mRNAs in pre-cancerous lesions and carcinomas of the
cervix, in human keratinocytes immortalized by HPV 16, and in cell
lines established from cervical cancers. Int. J. Cancer 50, 356–
364.
Shirasawa, H., Jin, M. H., Shimizu, K., Akutsu, N., Shino, Y., and Simizu,
B. (1994). Transcription-modulatory activity of full-length E6 and E6*1
proteins of human papillomavirus type 16. Virology 203, 36–42.
Spitkovsky, D., Aengeneyndt, F., Braspenning, J., and Doeberitz, M. V.
(1996). p53-independent growth regulation of cervical cancer cells by
the papillomavirus E6 oncogene. Oncogene 13, 1027–1035.
Stanley, M. A., Browne, H. M., Appleby, M., and Minson, A. C. (1989).
Properties of a nontumorigenic human cervical keratinocyte cell line.
Int. J. Cancer 43, 672–676.
Storey, A., and Banks, L. (1993). Human papillomavirus type 16 E6 gene
cooperates with EJ-ras to immortalize primary mouse cells. Onco-
gene 8, 919–924.
Tan, S. H., Gloss, B., and Bernard, H. U. (1992). During negative regu-
lation of the human papillomavirus-16 E6 promoter, the viral E2
protein can displace Sp1 from a proximal promoter element. Nucleic
Acids Res. 20, 251–256.
Thomas, M., Massimi, P., Jenkins, J., and Banks, L. (1995). HPV18-E6
mediated inhibition of p53 DNA binding activity is independent of E6
induced degradation. Oncogene 10, 261–268.
Vousden, K. H. (1993). Interactions of human papillomavirus transform-
ing proteins with the products of tumor suppressor genes. FASEB J.
7, 872–879.
Werness, B. A., Levine, A. J., and Howley, P. M. (1990). Association of
human papillomavirus types 16 and 18 E6 proteins with p53. Science
248, 76–79.
Zwerschke, W., Joswig, S., and Jansen-Du¨rr, P. (1996). Identification of
domains required for transcriptional activation and protein dimeriza-
tion in the human papillomavirus type-16 E7 protein. Oncogene 12,
213–220.
107HPV16, P53, AND ONCOGENES IN CERVICAL CELLS
